This site is intended for healthcare professionals

Review supports nutritional supplements use in hair loss treatment

Time : 5th of December 2022 10:09:55 AM Physician/Medicine,Nutrition & Fitness,Dermatology

The systematic review found high-quality evidence for potential benefits with omega 3 and 6 antioxidants, capsaicin, isoflavone, apple nutraceutical, glucosides of compound glycyrrhizin and paeony tablets, pumpkin seed oil, tocotrienol, zinc, and some supplement products. Low-quality evidence for benefits was found for vitamin D3, cheonggukjang, and kimchi.

EHSCS - A new scale to describe human skin colours

Time : 7th of October 2022 02:03:01 PM Dermatology

Researchers from the UK, Australia, France, and the US collaboratively developed Eumelanin Human Skin Colour Scale based on melanin index values. The scale includes five categories from low to high, with melanin index values ranging from less than 25 to more than or equal to 100. Experts saw encouraging results in evaluating and describing the skin colour of patients.
  British Association Dermatologists

FDA approves dupilumab as a treatment for prurigo nodularis

Time : 30th of September 2022 09:26:51 AM Pharma News,Dermatology

Regeneron Pharmaceuticals' Dupixent (dupilumab) became the first and only drug approved specifically for treating adults with prurigo nodularis, a chronic skin condition. Dupilumab has already received approvals for treating eosinophilic esophagitis, nasal polyposis, atopic dermatitis, and chronic rhinosinusitis in various patient populations across several countries.

Psoriasis drug shows benefits in cardiometabolic disease

Time : 28th of September 2022 10:51:27 AM Pharma News,Dermatology,Cardiology

Phosphodiesterase 4 inhibitor apremilast demonstrated a beneficial association with a series of cardiometabolic biomarkers and aortic vascular inflammation, as per a study. It also caused reductions in subcutaneous and visceral fat, suggesting potential benefits in cardiometabolic disease in individuals with psoriasis. Larger clinical trials are needed to confirm the benefits.
  HCP Live

EU endorses approval of tralokinumab for treating atopic dermatitis

Time : 21st of September 2022 11:45:37 AM Paediatrics,Otolaryngology,Dermatology

The CHMP gave a positive opinion on using Adtralza (tralokinumab) for treating adolescents aged 12-17 years with moderate-to-severe atopic dermatitis, as per a report. The recommended initial dose is 600 mg, followed by 300 mg every other week. The recommendation for approval of this human monoclonal antibody therapy was based on the results from the phase 3 ECZTRA 6 trial.
  Business Wire

Apremilast could benefit children with plaque psoriasis

Time : 20th of September 2022 01:47:16 PM Pharma News,Dermatology

Amgen announced the results of phase 3 trials on Otezla (apremilast), which demonstrated the drug's efficacy in treating moderate to severe plaque psoriasis in children and moderate to severe genital psoriasis in adults. The drug is an oral phosphodiesterase 4 inhibitor approved in 2014 with indications for plaque psoriasis and psoriatic arthritis in adults.

New treatment for eczema could help young kids

Time : 16th of September 2022 04:56:16 PM Pharma News,Paediatrics,Dermatology

Children aged 6 months to 6 years showed improvements in their symptoms within 2 weeks when treated with dupilumab, as per a study. Kids also had improvements in their quality of life and sleep. The findings could help get approval in the UK soon for treating young kids. The drug is already approved in the US for young kids and in the UK for kids aged 6 years and above.
  Manchester Evening News

FDA approves deucravacitinib for treating psoriasis

Time : 13th of September 2022 02:01:35 PM Pharma News,Dermatology

Sotyuku (deucravacitinib) is a first-in-class, selective TYK2 inhibitor approved fot treating patients with moderate-to-severe psoriasis. It is the first oral drug for psoriasis and the only TYK2 approved worldwide. The once-daily therapy improved skin clearance with a superior efficacy over twice-daily apremilast and placebo in phase 3 clinical trials. It was well-tolerated.
  Bristol Myers Squibb

FDA approves a neuromodulator to correct frown lines temporarily

Time : 12th of September 2022 10:58:29 AM Pharma News,Dermatology

DAXXIFY (DaxibotulinumtoxinA-lanm) is free of animal-based components and human serum albumin. It can be used to improve moderate to severe glabellar lines temporarily, thus addressing the duration of treatment effect. About 74% of participants achieved a 2-grade or above improvement on frown lines at week 4. It was safe and well-tolerated in the clinical trials.

Prior diagnoses could affect the dermatopathologists’ interpretations

Time : 24th of August 2022 02:22:07 PM Oncology,Diagnostics & Pathology,Dermatology

Dermatopathologists providing second opinions on the interpretation of melanocytic lesions should be blinded to prior diagnosis to obtain an independent and accurate diagnostic opinion, as per a study. It is because prior diagnoses swayed dermatopathologists away from a precise diagnosis to incorrect diagnoses and more or less severe diagnoses.
  Twitter @JAMADerm